INTRODUCTION
============

Within the last few years, the field of systemic therapy in medical oncology has seen two dramatic changes. First, the advances in the understanding of genetic abnormalities led to the discovery of various tumor driver mutations with the consequent development of different targeted therapies. Second, the better understanding of interaction between tumor cells and immune system led to the now much broader field of immuno-oncology and the consequent development of immunotherapies, which is currently being tested for treatment of different cancer types. In addition to these advances, a few new traditional chemotherapies have been approved and some already well-known treatments have had their indication broadened. Our objective is to review, for non-oncologists, the most recent advances of modern systemic cancer treatment.

TARGETED THERAPIES
==================

New technologies developed after the year 2000 allowed progressively more ambitious and thorough evaluation of tumors at molecular level. A major initiative has been the whole genome sequencing of various tumors, launched in 2005 as part of The Cancer Genome Atlas.^([@B1])^ So far, more than 20 different tumor types have been fully sequenced. The advances in the evaluation of genetic and epigenetic abnormalities and their consequences on the transcriptome have allowed a better understanding and further mapping of an intricate signaling pathway network, which characterizes the hallmarks of cancer cells.^([@B2],[@B3])^ The identification of driver mutations have crossed histologically driven tumor classifications, leading to a new way of looking at tumors, now based on the mutations rather than histology or organ in which the tumor arises. Although the identification of targets in tumor cells led to the development of various targeted therapies, we are now confronting the fact that these treatments have unfortunately not led to cure in metastatic cancers as once expected, despite the fact that outcomes such as progression free survival and overall survival have improved. In addition, before choosing the therapies, it is necessary to test the target, which sometimes requires sophisticated and costly techniques. Considering that some targets may be present in less than 5 to 10% of the patient population, many of them need to be tested in order to find one eligible for the targeted treatment. Adding the costs of tests and the drugs, these therapies are almost prohibitive for the Brazilian Public Health System, which prevent a significant majority of our population from receiving such treatments.

[Table 1](#t1){ref-type="table"} shows selected new targeted therapies made available in the last three years. Approval in Brazil has been limited, mainly due to regulatory delays, but certainly influenced by costs as well. The table describes the main indications, the targets for each drug and the most important outcomes reported in clinical trials.

Table 1Targeted therapiesReferenceTumor type (by organ)Name of drugMechanism of actionIndicationMain resultsAvailability in BrazilVerma et al.^(4)^BreastAdo-trastuzumab emtansine (T-DM1)Antibody-drug conjugate against Her2+ cellsMetastatic Her2+ breast cancer, after failing trastuzumab and taxaneImproved PFS and overall survival compared with lapatinib and capecitabineRegistered in Brazil. Not available in Brazilian Public Health SystemSwain et al.^(5)^BreastPertuzumabHer2 inhibitionMetastatic Her2+ breast cancerImproved PFS and overall survival compared with trastuzumab and taxaneRegistered in Brazil. Not available in Brazilian Public Health SystemPiccart et al.^(6)^BreastEverolimusmTOR inhibitorMetastatic HR+ and Her2- breast cancer in combination with exemestaneImproved PFS compared with second line exemestane aloneRegistered in Brazil. Not available in Brazilian Public Health SystemTurner et al.^(7)^BreastPalbociclibCDK4 and CDK6 inhibitorMetastatic HR+ and Her2- breast cancer in combination with fulvestrantImproved PFS compared with second line Fulvestrant aloneNot registered in BrazilTewari et al.^(8)^CervixBevacizumabVEGF inhibitorMetastatic cervical cancerImproved overall survival when added to chemotherapyRegistered in Brazil. Not available in the Brazilian Public Health SystemGrothey et al.^(9)^ColorectalRegorafenibMultikinase inhibitorPreviously treated metastatic colorectal cancerModest improvement in overall survival compared with supportive care aloneNot registered in BrazilFuchs et al.^(10)^GastricRamucirumabVEGFR2 antagonistInoperable gastric or gastroesophageal junction adenocarcinoma after prior chemotherapyImproved survival compared with placeboNot registered in BrazilDemetri et al.^(11)^GISTRegorafenibMultikinase inhibitorMetastatic GIST after standard treatment with imatinib and sunitinibImproved PFS compared with placeboNot registered in BrazilWu et al.^(12)^; Sequist et al.^(13)^LungAfatinibEGFR inhibitorMetastatic NSCLC with EGFR exon 19 deletion or L858R EGFR mutationImproved PFS compared with gemcitabine and cisplatin or with cisplatin and pemetrexedNot registered in BrazilShaw et al.^(14,15)^LungCrizotinibALK inhibitor, ROS1 inhibitorMetastatic NSCLC with ALK-EML4 fusion, or with ROS1 rearrangementImproved PFS compared with pemetrexed in platinum refractory diseaseNot registered in BrazilShaw et al.^(16)^LungCeritinibALK inhibitorMetastatic ALK-rearranged NSCLCResponses in naïve and crizotinib pretreated diseaseNot registered in BrazilChapman et al.^(17)^MelanomaVemurafenibBRAF inhibitorMetastatic melanoma with BRAF V600E mutationImproved overall survival and PFS compared with DacarbazineRegistered in Brazil. Not available in the Brazilian Public Health SystemRobert et al.^(18)^MelanomaDabrafenibBRAF inhibitorMetastatic melanoma BRAF V600E mutationImproved overall survival when combined with Trametinib, compared with VemurafenibNot registered in Brazil.Robert et al.^(18)^MelanomaTrametinibMEK inhibitorMetastatic Melanoma with BRAF V600E or V600K mutationImproved overall survival when combined with Dabrafenib, compared with VemurafenibNot registered in BrazilLedermann et al.^(19)^OvaryOlaparibInhibitor of poly (ADP-ribose) polymeraseBRCA mutated advanced ovarian cancerImproved PFS compared with placebo in platinum sensitive relapseNot registered in BrazilBrose et al.^(20)^ThyroidSorafenibMulti-kinase inhibitorMetastatic differentiated thyroid cancer refractory to radioactive iodineImproved PFS compared with placeboNot registered in Brazil for this indicationSchlumberger et al.^(21)^ThyroidLenvatinibVEGF receptor inhibitor, PDGFR inhibitor, RET and KITMetastatic differentiated thyroid cancer refractory to radioactive iodineImproved PFS compared with placeboNot registered in BrazilElisei et al.^(22)^Medullary thyroidCabozantinibMET, VEGFR2 and RET inhibitorProgressive metastatic medullary thyroid cancerImproved PFS compared with placeboNot registered in BrazilWells et al.^(23)^Medullary thyroidVandetanibRET kinase inhibitor and VEGF inhibitorProgressive metastatic medullary thyroid cancerImproved PFS compared with placeboNot registered in Brazil[^1]

Some targeted therapies that have been approved and made available in the private health system in Brazil for several years still have limited access in the Brazilian Public Health System. Some examples are trastuzumab for metastatic Her2+ breast cancer; erlotinib and gefitinib for epidermal growth factor receptor (EGFR) mutated metastatic lung cancer; cetuximab and panitumumab for RAS-wild type metastatic colorectal cancer, in addition to several treatments used in hematological malignancies, which are not the focus of this report. Some other targeted treatments have been available for several years in North America and/or Europe, but they are still not registered in Brazil. Examples are aflibercept for colorectal cancer, pazopanib and trabectedine for soft tissue sarcomas, and axitinib for renal cell carcinoma.

IMMUNOTHERAPY
=============

Human immune system has been known for quite some time for recognizing tumor antigens and mounting an immune response, although the actual explanation for the variability in tumor control by the immune system remains elusive. Cancer cells are capable of evading the immune surveillance by suppressing tumor-directed immunity through mechanisms described over the last two decades.^([@B24])^ It occurs by inhibiting helper and cytotoxic T cells while stimulating regulatory T cells instead. Inhibitory mechanisms determined by cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4), programmed death 1 (PD1) and its ligand programmed death ligand 1 (PD-L1) can currently be targeted and inhibited by new immunotherapies, which lead to unblocking the immune response. This will ultimately unleash an immune attack on cancer cells. Anti-CTLA-4 antibodies as well as PD1 and PD-L1 inhibitors are already approved and used to treat a limited number of tumor types (melanoma and lung cancer), and promising preliminary results indicate potential future use in a large variety of cancers.

[Table 2](#t2){ref-type="table"} outlines the new immunotherapies, its approved indications, mechanism of action and main results in clinical trials.

Table 2ImmunotherapiesReferenceTumor type (by organ)Name of drugMechanism of actionIndicationMain resultsAvailability in BrazilHodi et al.^(25)^; Robert et al.^(26)^MelanomaIpilimumabAnti-CTLA-4Metastatic melanomaImproved overall survival compared with gp100 vaccine and improved overall survival when added to dacarbazine compared with dacarbazine aloneRegistered in Brazil. Not available in the Brazilian Public Health SystemRobert et al.^(27)^ e Weber et al.^(28)^MelanomaNivolumabAnti-PD1Metastatic melanoma without BRAF mutation or after progression on Ipilimumab and BRAF inhibitorImproved overall survival and progression free survival compared with dacarbazineNot registered in BrazilRobert et al.^(29)^MelanomaPembrolizumabAnti-PD1Metastatic melanomaImproved overall survival and progression free survival compared with ipilimumabNot registered in BrazilBrahmer et al.^(30)^LungNivolumabAnti-PD1Metastatic NSCLC, squamous histologyImproved overall survival, progression free survival and response rate compared with DocetaxelNot registered in BrazilGaron et al.^(31)^LungPembrolizumabAnti-PD1Metastatic NSCLCSignificant antitumor activityNot registered in Brazil[^2]

The successful combination of two immunotherapies was already reported. Combined nivolumab and ipilimumab had better results than either drug alone to treat metastatic melanoma.^([@B32],[@B33])^ Both nivolumab and pembrolizumab, as well as other anti-PD1, anti PD-L1 and combinations with anti-CTLA-4, are under test for a variety of tumors, with some extraordinary preliminary results. Positive results with these immunotherapies have been reported in kidney, bladder, pancreatic, metastatic colorectal cancer related to Lynch syndrome, gastroesophageal cancer and glioblastoma, among others. Of note, although, is that for most diseases exist a clear correlation of benefit with the higher expression of PD-L1 on tumor cells,^([@B34],[@B35])^ and there is still no standardized evaluation for the expression of PD1 or PD-L1. An unique aspect related to immunotherapies is sometimes the significant delayed response, which has been reported both with anti-CTLA-4 as well as anti- -PD1 inhibitors.^([@B36],[@B37])^ This highlights the need for careful consideration before deeming these drugs ineffective, and it has led to the establishment of a different set of response criteria, known as immune-related response criteria (irRC).^([@B38])^ Immune related adverse events derive from the activation of autoimmune-mediated diseases in the skin, gastrointestinal tract, liver and endocrine system. The most clinically relevant adverse event is diarrhea, which may have late onset and be life threatening if not rapidly and properly treated.

OTHER NEW SYSTEMIC TREATMENTS
=============================

In addition to the new targeted therapies and immunotherapies, few other new treatments (with various mechanisms of action) with significant clinical impact have emerged and been approved for clinical use in recent years.

[Table 3](#t3){ref-type="table"} describes new systemic treatments, its indications, mechanisms of action and main results in clinical trials.

Table 3Other new cancer therapiesReferenceTumor type (by organ)Name of drugMechanism of actionIndicationMain resultsAvailability in BrazilRyan et al.^(39)^ProstateAbirateroneBlocks cytochrome P450 17 alpha-hydroxilase reducing androgen productionMetastatic castration resistant prostate cancerImprovement in overall survival compared with prednisoneRegistered in Brazil. Not available in the Brazilian Public Health SystemBeer et al.^(40)^ProstateEnzalutamideAndrogen receptor blocker and androgen receptor signal inhibitorMetastatic Castration resistant prostate cancerImprovement in overall survival compared with placeboRegistered in Brazil for castration and chemotherapy refractory disease. Not available in Brazilian Public Health SystemSweeney et al.^(41)^; James et al.^(42)^ProstateDocetaxelInterferes with mitotic spindleUpfront treatment of castration sensitive metastatic prostate cancerImprovement in overall survival when added to castration, compared with castration aloneRegistered in Brazil. Available in the Brazilian Public Health SystemParker et al.^(43)^ProstateRad 223 dichlorideAlpha emitter that targets bone metastasesMetastatic (to the bones) castration resistant prostate cancerImproved overall survival compared with placeboRegistered in Brazil. Not available in the Brazilian Public Health SystemCortes et al.^(44)^BreastEribulin mesilateMicrotubule inhibitorPreviously treated metastatic breast cancerImproved overall survival compared with treatment of physicians choiceRegistered in Brazil. Not available in the Brazilian Public Health System

There is currently a very vivid discussion around the world about the significant costs associated with new cancer therapy in general, and specifically about anti-cancer drugs. Immunotherapies, which seem to be on their way to become indicated for a large proportion of cancer patients, and some of the newer targeted therapies can cost hundreds of thousands of dollars per patient annually.^([@B45])^ Cost is certainly a significant limiting factor for these drugs becomes available in Brazil.

Some good cancer treatments are still under registration process in Brazil, highlighting the gap between what is practice here in comparison with developed countries. No less important is the significant difference between what is registered and used in the private health system and what is available and used in the Brazilian public health system. Unless pricing of drugs becomes more reasonable in the near future, and unless health technology evaluation for the public health system starts to be dictated by well-established standards and pre-specified cost-effectiveness limits, new cancer therapies will be ever more limited in developing countries like Brazil, and as a consequence the difference between what is practiced internationally and in our country will widen significantly.

[^1]: T-DM1: Kadcyla; Her2: human epidermal growth factor receptor 2; PFS: progression-free survival; CDK: cyclin-dependent kinase; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial growth factor receptor; GIST: gastrointestinal stromal tumor; EGFR: epidermal growth factor receptor; NSCLC: non small cell lung cancer; ALK: anaplastic lymphoma kinase; ROS1: ROS proto-oncogene 1; BRAF: proto-oncogene B-Raf; MEK: mitogen activated protein kinase; BRCA: breast cancer gene; PDGFR: platelet derived growth factor receptor; MET: hepatocyte growth factor receptor; RET: rearranged during transfection; KIT: proto-oncogene c-Kit.

[^2]: CTLA-4: cytotoxic T-lymphocyte-associated antigen-4; PD1: programmed death 1; BRAF: proto-oncogene B-Raf; NSCLC: non small cell lung cancer.
